Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The design, pharmacology, and toxicology exploring of a novel chemically modified siRNA targeting hepatic angiotensinogen with potential application for hypertension treatment

ABSTRACT: The design, pharmacology, and toxicology exploring of a novel chemically modified siRNA targeting hepatic angiotensinogen with potential application for hypertension treatment

PROVIDER: PRJNA1234092 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32632300_1.fastq.gz	Fastqsanger.gz
	SRR32632300_2.fastq.gz	Fastqsanger.gz
	SRR32632301_1.fastq.gz	Fastqsanger.gz
	SRR32632301_2.fastq.gz	Fastqsanger.gz
	SRR32632302_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 264

Similar Datasets

The design, pharmacology, and toxicology exploring of a novel chemically modified siRNA targeting hepatic angiotensinogen with potential application for hypertension treatment

Project description:Angiotensinogen is the precursor of angiotensin II, a potent vasopressor in the renin-angiotensin-aldosterone system. Small interfering RNAs targeting hepatic angiotensinogen have been proven to be effective on blood pressure lowering in hypertension patients through reducing AGT levels in blood, and such effect could last over 6 months. Existing siRNA molecules has been high effective. However, it may be possible to develop novel siRNA molecules with improved inhibitory activity and longer duration period. In this study, we demonstrated an entire development process for a novel siRNA targeting hepatic angiotensinogen. Through proper combination of bioinformatics on-target/off-target screening on sequences, chemical modification patterns and liver-targeting delivery ligands, we have developed siRNA molecules with equivalent or better inhibitory activity, duration of effect and safety profile compared with siRNA molecules discovered previously. Furthermore, our analysis also revealed the correlation between efficacy and free energy of siRNAs. At present, no model can accurately predict the activity and off-target risk of fully modified siRNA molecules, thus efficient screening procedures are essential during the development of siRNA candidates. This study has provided a detailed and useful reference for the development of potent and safe siRNAs, which could also guide the future development of siRNAs on other targets.

2025-04-21 | GSE291523 | GEO

Genome-wide analysis of gene expression in white adipose tissue in angiotensinogen overexpression transgenic and wild type male B6 mice

Project description:Investigation of differential gene regulation with overexpression of angiotensinogen in white adipose tissue. We hypothesized that angiotensinogen overexpression will disrupt metabolic homeostasis of adipocytes leading to obesity and related chronic diseases. Results indicate that angiotensinogen overexpression differentially regulate genes related metabolic functions in adipose tissue.

2020-07-15 | GSE149231 | GEO

Angiotensinogen and C3 compete for renin-induced complement activation

Project description:Demonstration of renin cleavage of C3. Angiotensinogen and C3 compete for renin-induced complement activation.

2025-04-18 | PXD053116 | Pride

Toxicology study on KhES-3 cells.

Project description:Perform microarray study to select sensitive genes for toxicology analysis on hESC validation system.

2014-08-07 | GSE60154 | GEO

Development of chemically modified peptide targeting BIG3-PHB2 interaction on estrogen-dependent breast cancer

Project description:Our previous studies demonstrated that specific inhibition of the BIG3-PHB2 complex, which is indispensable for estrogen (E2)-signaling activation, using ERAP, a dominant-negative peptide inhibitor, leads to the suppression of E2-dependent breast cancer cell growth in vitro and in vivo. However, duration of its effect is very short for clinical use. Here, we developed the chemically modified ERAP using stapling methods (stERAP; stapled ERAP) to improve duration of their antitumor effects. Tumor bearing mice treated with every 4 and 7 days with stERAP (1 mg/kg body weight) treatment effectively prevented the BIG3-PHB2 interaction, thereby releasing PHB2 to directly bind to both nuclear- and cytoplasmic ERalpha. This event led to the complete suppression of the E2-signalling pathways and ERalpha-positive breast cancer cell growth both in vitro and in vivo, but did not suppress the growth of normal mammary epithelial cells. Our findings suggest that the chemically modified stERAP may be a promising anti-tumor drug to suppress the growth of luminal-type breast cancer in clinical use.

2017-06-09 | GSE87378 | GEO

Transcriptomics profiling of ccc_R08 for mechanism-of-action investigation with forward pharmacology

Project description:To investigate the mode of action of ccc_R08, a first-in-class orally available HBV cccDNA inhibitor, we designed and implemented two orthogonal and complementary approaches: a forward pharmacology approach and a reverse pharmacology approach. Bioinformatics analysis integrating biological knowledge with the observations from both approaches offered us preliminary insights into the mode of action of ccc_R08.

2022-12-30 | GSE214515 | GEO

Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Project description:The study of botulinum neurotoxins (BoNT) is rapidly progressing in many aspects. Novel BoNTs are being discovered owing to next generation sequencing, but their biologic and pharmacological properties remain largely unknown. The molecular structure of the large protein complexes that the toxin forms with accessory proteins, which are included in some BoNT type A1 and B1 pharmacological preparations, have been determined. By far the largest effort has been dedicated to the testing and validation of BoNTs as therapeutic agents in an ever increasing number of applications, including pain therapy. BoNT type A1 has been also exploited in a variety of cosmetic treatments, alone or in combination with other agents, and this specific market has reached the size of the one dedicated to the treatment of medical syndromes. The pharmacological properties and mode of action of BoNTs have shed light on general principles of neuronal transport and protein-protein interactions and are stimulating basic science studies. Moreover, the wide array of BoNTs discovered and to be discovered and the production of recombinant BoNTs endowed with specific properties suggest novel uses in therapeutics with increasing disease/symptom specifity. These recent developments are reviewed here to provide an updated picture of the biologic mechanism of action of BoNTs, of their increasing use in pharmacology and in cosmetics, and of their toxicology.

| S-EPMC5394922 | biostudies-literature

Chemically-induced osteogenic cells (ciOG)

Project description:Chemically-induced osteogenic cells (ciOG)

| PRJNA849336 | ENA

Deciphering risperidone-induced lipogenesis by network pharmacology and molecular validation

Project description:Risperidone is an atypical antipsychotic that can cause substantial weight gain. The pharmacological targets and molecular mechanisms related to risperidone-induced lipogenesis (RIL) remain to be elucidated. Therefore, network pharmacology and further experimental validation were undertaken to explore the action mechanisms of RIL. In this study, RIL was systematically analyzed using integrating multiple databases through integrated network pharmacology, transcriptomics, molecular docking, and molecular experiment analysis. The potential signaling pathways for RIL were identified and experimentally validated using Gene Ontology (GO) enrichment and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Our experimental data showed that Risperidone promotes adipocyte differentiate and lipid accumulation. And network pharmacology and GO analyses showed that risperidone induced adipocyte metabolism, differentiation, and lipid accumulation related functions. Intersecting analysis, molecular docking, and pathway validation analysis indicated that risperidone activated adipocytokine signaling pathway related genes by targeting MAPK14 (Mitogen-activated protein kinase 14), MAPK8 (Mitogen-activated protein kinase 8), and RXRA (Retinoic acid receptor RXR-alpha), thereby inhibiting long-chain fatty acid beta-oxidation by suppressing STAT3 (Signal transducer and activator of transcription 3) expression and phosphorylation. This study suggested that Risperidone increases adipocyte lipid accumulation by plausible inhibiting long-chain fatty acid beta-oxidation through targeting MAPK14, MAPK8, and RXRA.

2022-05-11 | GSE198053 | GEO

Brucine: A Review of Phytochemistry, Pharmacology, and Toxicology.

Project description:Brucine, a weak alkaline indole alkaloid, is one of the main bioactive and toxic constituents of Nux-vomica. Modern pharmacology studies and clinical practice demonstrate that brucine possesses wide pharmacological activities, such as anti-tumor, anti-inflammatory, analgesic, and the effects on cardiovascular system and nervous system, etc. However, its central nervous system toxicity severely limits its clinical application. Herein, the physicochemical properties, pharmacological activities, and toxicity of brucine were reviewed, and the novel strategies to address the toxicity issues were discussed, aiming to bring new insights into further research and application of this active component.

| S-EPMC7145893 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data